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1. Introduction 
Melanoma incidence has been growing fast, however the only efficient available treatment is 
the surgical excision of the affected area when the tumor is detected early. Once diagnosed 
with metastatic melanoma, most patients have an overall surviving time of 2 years (Howell 
et al., 2009). Melanoma aggressive nature has encouraged many researchers to study 
possible molecular alterations behind disease development and progression. During many 
years the focus of studies on melanoma field was genetic alterations. Despite their 
importance in familial cases, mutation accumulation does not well explain sporadic tumor 
cases that can take many years to develop. In the past decades, growing attention has been 
given to the participation of epigenetic alterations, together with mutations, in the aetiology 
of cancer. Epigenetic marks control gene expression without altering the primary DNA 
sequence and are potentially reversible by epigenetic drugs. In a different way of mutations, 
epigenetic marks are plastic and can be influenced by environmental changes. Therefore, 
aberrant epigenetic patterns could explain the relationship between cancer and environment 
injury, since chronic injury is one of the causes for increased cancer risk (Bjornsson et al., 
2004). In melanoma specifically, UV radiation and inflammation are considered as risk 
factors and epigenetic mechanisms could be the link between environmental insult and 
tumor formation and progression (Autier et al., 2011; Gallagner et al., 2010). The epigenetic 
mechanisms include DNA methylation, histone modifications, nucleosome remodeling and 
micro-RNAs (miRNAs). Collectively these mechanisms regulate the genetic information 
accessibility, promoting in this way the cellular diversity. In the next sections, the 
importance of epigenetics in melanoma will be discussed, as well their possible relation with 
environmental injuries. 
2. Epigenetics and cancer 
Cancer disease is complex and involves many factors including aberrant epigenetic alterations. 
Epigenetic is the study of hereditable patterns of gene expression that do not involve 
modifications in the primary DNA sequence. These heritable marks are established during 
embryonic development and stably maintained through cellular division (Reik, 2007). While 
the genome is the same in each cell type of an individual, the epigenome differs from tissue 
to tissue and is essential to maintain cellular identity (Mikkelsen et al., 2007). Therefore, its 
disruption could lead to inappropriate gene expression contributing to diseases such as 
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cancer (Egger et al., 2004). Epigenetic mechanisms comprise DNA methylation, histone 
modifications, chromatin remodeling and RNA associated silencing by micro-RNAs 
(miRNAs). These mechanisms work together to regulate the functioning of the genome.  
2.1 DNA methylation in cancer 
DNA methylation is the most studied epigenetic mechanism, is generally linked to stable 
gene expression inactivation and normally occurs in mammals by the covalent modification 
of the CpG dinucleotide (cytosine to 5-methylcytosine). CpG distribution is not random in 
mammal genome. There are regions with high CpG frequency called CpG islands. 
Generally, these islands are located at 5’ end of about 60% of human genes. Although some 
of these islands (about 6%) become methylated in a tissue-specific manner during 
development or in differentiated tissues, they are commonly unmethylated in normal cells 
(Straussman et al., 2009). One of the hallmarks of cancer cells is the presence of an aberrant 
DNA methylation pattern, which is characterized by specific DNA hypermethylation of 
tumor suppressor gene promoters and global DNA hypomethylation compared to normal 
cells. The hypermethylation of tumor suppressor promoters is associated with loss of their 
expression. Global DNA hypomethylation can contribute to genomic instability because it is 
largely a consequence of DNA methylation loss in non-coding DNA (like repetitive DNA 
sequences) and transposable elements (Rodriguez et al., 2006). Besides that, DNA 
hypomethylation can also cause oncogene activation (Jun et al., 2009).  
2.2 Histone modifications in cancer 
Posttranslational histone modifications, such as acetylation and methylation of lysine 
residues, have also a crucial role in controlling gene expression (Smith & Shilatifard, 2010.). 
Unlike DNA methylation, histone modifications can lead to either activation or inactivation. 
Overall, lysine acetylation is linked to gene activation whereas lysine methylation can be a 
marker for both, gene activation in the case of H3K4 trimethylation or repression in the case 
of H3K27 and H3K9 trimethylation. Histone posttranslational modification patterns and 
enzymes catalyzing the addition or removal of histone marks have been found altered in 
cancer, as well proteins that are specifically recruited by these modifications, such as 
polycomb group proteins, DNA methylltransferases (DNMTs) and nucleosome remodeling 
factors (Sharma et al., 2010). Non-covalent mechanisms, such as nucleosome remodeling, 
also contribute to regulate the gene activity (Svejstrup, 2010). In addition to their role as a 
basic organization for DNA packaging, nucleosome positioning regulates gene expression 
by altering DNA accessibility to transcriptional factors (Jiang & Pugh, 2009). The role of such 
mechanism in cancer is not well understood; nevertheless, recent data have been shown that 
nucleosome remodeling machinery seems to work together with histone modifications and 
DNA methylation in tumor-specific gene silencing (Morey et al., 2008).  
2.3 Micro-RNAs in cancer 
Another mechanism recently considered as epigenetic is RNA associated silencing by micro-
RNAs. Micro-RNAs (miRNAs) are small non-coding RNAs that regulate gene expression 
through posttranscriptional silencing of target genes (Peter, 2010). Micro-RNAs are 
expressed in a tissue specific manner and can control many important biological processes 
including cell proliferation, apoptosis and differentiation. They can function as tumor 
suppressors or oncogenes, depending on their target genes (Peter, 2010). There is a growing 
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number of miRNAs found aberrantly expressed in cancer cells and this abnormal expression 
seems to be tumor-specific (Lu et al., 2005). Moreover, miRNA expression can be regulated 
by many processes, including epigenetic mechanisms, such as DNA methylation and 
histone modifications (Deng et al., 2008). 
Besides their individual roles, epigenetic mechanisms interact with each other to determine 
gene expression status and this interaction is crucial to promote properly chromatin 
architecture and gene activity during development and to maintain cellular identity after 
cell commitment process (Cerda & Bergman, 2009). Consequently, it has been shown that 
aberrant changes in epigenetic marks can compromise cell fate and participate in the early 
phases of cell malignant transformation (Feinberg et al., 2006). Different of mutations, these 
modifications can be reversible by chemical components and/or by environment and this 
reversible nature led to the development of a promising field: ”The epigenetic therapy”. In 
this way, this book chapter proposes to discuss what is known about the epigenome of 
melanoma, the emerging relation among stress, epigenetics and melanoma and the 
perspectives regarding epigenetic therapies to treat this metastatic disease. 
3. Epigenetics and melanoma 
The importance of epigenetic mechanisms in cancer formation and progression has been 
growing in the past decades. Despite of this, there are less published studies about abnormal 
epigenetic marks in melanoma than in any other cancer type. Additionally, most of the 
studies in literature refer to tumor suppressor genes silenced by DNA hypermethylation 
and few of them focus on posttranslational histone modifications, nucleosome remodeling 
and miRNAs. In the next sections, data concerning the epigenetic marks mentioned before 
will be discussed in melanoma. 
3.1 The methylome of melanoma 
3.1.1 Tumor suppressor genes silenced by DNA hypermethylation in melanoma 
Melanoma development, as other tumors, is accompanied by disruption of cellular DNA 
methylation homeostasis, resulting in both hypermethylation of tumor suppressor 
promoters and genome wide hypomethylation (Molognoni et al., 2011; Soengas et al., 2001; 
Tenemura et al., 2009; Van Doorn et al., 2005). 
Aberrant CpG island hypermethylation is a common event in melanoma and an important 
mechanism to shut off tumor suppressor genes (TSGs) involved in all key pathways of 
tumor development and progression, including cell cycle regulation, cell signaling, 
differentiation, DNA repair, apoptosis, invasion and immune system recognition (Sigalloti 
et al., 2010). Hypermethylation patterns are tumor-specific and it is still unclear why some 
DNA regions become hypermethylated, whereas others remain unmethylated. Most of the 
studies in the field of melanoma epigenetics describe hypermethylation of tumor suppressor 
genes. The great interest in this topic has an explanation: the considerable prognostic, 
diagnostic and therapeutic value of these studies. Because of that, some authors have been 
described the CpG island methylator phenotype (CIMP), which refers to the coordinated 
inactivation of tumor supressor and tumor-related genes in a determined type of cancer 
(Toyota et al., 1999). In addition, these epigenetic changes would create a distinct CIMP 
pattern that could be associated to the disease stage, recurrence and patient survival 
(Tanemura et al., 2009). At least 60 tumor suppressor genes have been identified to date as 
silenced by DNA hypermethylation in melanoma (Table 1). Some of them will be discussed 
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in more details. A well-studied example of DNA hypermethylation in melanoma is 
CDKN2A locus. This locus encodes two proteins which are cell cycle regulators through pRB 
and p53 pathways (p16INK4A and p14ARF, respectively). Aberrant DNA hypermethylation at 
CDKN2A locus can independently affect p16INK4A and p14ARF, which are methylated in 27% 
and 57% of metastatic melanoma samples, respectively (Freedberg et al., 2008). In addition, 
CDKN2A locus is one of the well-known cases in which genetic alterations can cooperate 
with DNA methylation to promote gene inactivation (Freedberg et al., 2008; Gonzalgo et al., 
1997). In this way, gene deletion can eliminate one allele and DNA hypermethylation silence 
the remaining one. This cooperation might be responsible for the concomitant inactivation of 
p16INK4A and p14ARF in a significant percentage of metastatic melanoma. Another important 
tumor suppressor which expression is lost by DNA hypermethylation in melanomas is 
APAF-1, a cell death effector that mediates p53-dependent apoptosis (Soengas et al., 2001). 
Then, the successfully shut off of CDKN2A locus and APAF-1 by DNA hypermethylation 
and/or mutations could be a way utilized by melanoma cells to evade the growth arrest 
triggered by p53, once p53 is rarely mutated in melanomas (Soussi & Beroud, 2001). PTEN is 
another important gene which activity loss by DNA hypermethylation has been reported to 
contribute to the melanoma development (Mirmohammadsadegh et al., 2006). PTEN gene 
encodes a phosphatase that degrades PI3K products and its function loss can cause 
accumulation of PI3K messenger lipids, which in turn increase AKT phosphorylation and 
activity, leading to apoptosis decrease (Lian et al., 2005). Mirmohammadsadegh and co-
workers (2006) observed an increase in PTEN CpG island methylation in primary, metastatic 
melanoma and serum from melanoma patients. Moreover, metastatic disease showed the 
higher DNA methylation percentage compared to primary tumor. 
Besides the classical examples, there are other genes that have been found hypermethylated 
in melanomas such as RAR-┚2, SOCS1 and SOCS2. RAR-┚2, which mediates growth arrest, 
apoptosis and differentiation triggered by retinoic acid (RA), has been found 
hypermethylated in 70% of melanoma lesions (Hoon et al., 2004). Interestingly, RAR-┚2 
promoter hypermethylation is found with similar frequency in primary and metastatic 
melanoma lesions, suggesting that this hypermethylation process might be an early event in 
melanoma disease (Hoon et al., 2004). SOCS’s family genes have been implicated in the 
regulation of signal transduction by a variety of cytokines (Fujimoto & Naka, 2003). 
Moreover, SOCS1 restoration suppressed both growth rate and anchorage independent 
growth of cells in which SOCS1 was silenced by promoter methylation (Yoshikawa et al., 
2001). One study using 20 melanoma cell lines and 40 freshly isolated advanced stage 
melanoma tumors showed around 90% and 80% of DNA methylation in SOCS1 and SOCS2 
promoter, respectively (Liu et al., 2008). This methylation percentage was similar in 
melanoma cell lines and freshly isolated tumors. In addition, at the same work, RAR-┚2 was 
found with 60% of methylation both in cell lines and freshly isolated advanced stage 
melanoma tumors. Summarizing there are many tumor suppressor genes silenced by 
promoter hypermethylation in melanoma and it will be necessary to continue looking for 
other key genes to provide novel targets for diagnosis and therapy. 
3.1.2 Aberrant DNA hypomethylation in melanoma 
Global DNA hypomethylation found in cancer cells is largely a consequence of DNA 
methylation loss in repetitive elements, which in turn, as mentioned before, could contribute 
to genomic instability and transposon elements activation (Portela & Esteller, 2010). A clear 
case of repetitive element hypomethylation in cancer is the LINE family member LINE-1, 
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Pathway Gene Common Name References 
Apoptosis DAPK1 
HSPB6 
HSPB8 
HSP11 
RASSF1A 
TNFRSF10C
TNFRSF10D
APAF-1 
Death- associated protein 1 
Heat shock protein, alpha crystalin related, B6 
Heath shock 22 kDa protein 8 
Heat shock protein H11 
Ras association domain family protein 1A 
Tumor necrosis factor receptor superfamily member 10C
Tumor necrosis factor receptor superfamily member 10D
Apoptotic protease activating factor 1 
Hoon et al., 2004 
Koga et al., 2009 
Sharma et al., 2006 
Sharma et al., 2006 
Spugnardi et al., 2003 
Liu et al., 2008 
Liu et al., 2008 
Soengas et al., 2001 
Cell cycle CDKN1C 
CDKN2A 
TSPY 
Cyclin-dependent kinase inhibitor 1C 
Cyclin-dependent kinase inhibitor 2A 
Testis specific protein, Y linked 
Muthusamy et al., 2006 
Freedberg et al., 2008 
Gallagher et al., 2005 
Cell fate 
determination 
MIB2 
APC 
WIF1 
mindbomb homolog 2 
Adenomatous polyposis coli gene 
Wnt inhibitory factor 1 
Takeuchi et al., 2006 
Worm et al., 2004 
Tenemura et al., 2009 
Chromatin 
remodeling 
NPM2 Nucleophosmin/nucleoplasmin 2 Koga et al., 2009 
Degradation of 
misfold proteins 
DERL3 Der1 like domain family member 3 Furuta et al., 2006 
Differentiation GDF15 
HOXB13 
Growth differentiation factor 15 
homeobox B13 
Muthusamy et al., 2006 
Muthusamy et al., 2006 
DNA repair MGMT O-6-methylguanine-DNA methyltransferase Hoon et al., 2004 
Drug metabolism CYP1B1 
DNAJC15 
Cytochrome P450, family 1, subfamily B, polypeptide 1 
DnaJ (Hsp40) homolog, subfamily C, member 15 
Muthusamy et al., 2006 
Muthusamy et al., 2006 
Extracellular matrix COL1A2 
MFAP2 
Collagen, type I, alpha 2 
Microfibrillar-associated protein 2 
Koga et al., 2009 
Muthusamy et al., 2006 
inflammation PTGS2 Prostaglandin-endoperoxide synthase 2 Muthusamy et al., 2006 
metastasis CDH1 
CDH8 
CDH13 
SERPINB5 
LOX 
THBD 
E-cadherin 
Cadherin 8, type 2 
Cadherin 13, H-cadherin 
Serpin peptidase inhibitor, clade B, member 5 
Lysyl oxidase 
Thrombomodulin 
Tellez et al., 2009 
Muthusamy et al., 2006 
Tellez et al., 2009 
Denk et al., 2007 
Liu et al., 2008 
Liu et al., 2008 
Proliferation WFDC1 WAP four-disulfide core domain 1 Liu et al., 2008 
ER┙ 
PGR┚ 
PTEN 
Estrogen receptor α 
Progesterone receptor β 
Phosphatase and tensin homolog 
Mori et al., 2006 
Tellez et al., 2009 
Mirmohammadsadegh 
et al., 2006 
Signaling 
3-OST-2 
RARRES1 
RAR┚2 
RIL 
SOCS1 
SOCS2 
SOCS3 
Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 
Retinoic acid receptor responder 1 
Retinoic acd receptor β2  
Reversion-induced LIM 
Supressor of cytokin signaling 1 
Supressor of cytokine signaling 2 
Supressor of cytokine signaling 3 
Furuta et al., 2006 
Bonazzi et al., 2009 
Hoon et al., 2004 
Tellez et al., 2009 
Liu et al., 2008 
Liu et al., 2008 
Tokita et al., 2007 
Transcription 
 
 
 
 
HAND1 
OLIG2 
NKX2-3 
PAX2 
PAX7 
GATA4 
Heart and neural crest derivatives expressed 1 
Oligodendrocyte lineage transcription factor 2 
Homeobox protein Nkx-2.3  
Paired box 2 
Paired box 7 
GATA binding protein 4 
Furuta et al., 2004 
Tellez et al., 2009 
Tellez et al., 2009 
Tellez et al., 2009 
Tellez et al., 2009 
Atsushi et al., 2009 
To be determined BST2 
LXN 
QPCT 
Bone marrow stromal cell antigen 2 
Latexin 
Glutaminyl-peptide cyclotransferase 
Muthusamy et al., 2006 
Muthusamy et al., 2006 
Muthusamy et al., 2006 
Table 1. Genes found hypermethylated in melanoma 
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which has been shown hypomethylated in a wide range of cancers (Portela & Esteller, 2010). 
Tellez and co-workers (2009) showed 75% of hypomethylation in LINE-1 repetitive sequence 
when they analyzed 16 melanoma cell lines by pyrosequencing. Additionally, DNA 
hypomethylation at specific promoters can activate expression of oncogenes and induce loss 
of imprinting (Herman & Baylin, 2003). In melanoma, a group of cancer-testis antigens and 
other genes considered as oncogenes have been shown to be hypomethylated (Howell et al., 
2009). Melanoma antigen (MAGE) genes, for example, are normally only expressed by male 
germline cells. In somatic cells, their expression is silenced by promoter hypermethylation. 
Nevertheless, in malignant melanoma, aberrant expression of MAGE genes occurs and is 
associated with DNA hypomethylation (De Smet et al., 1996; Sigalotti et al., 2002). Recent 
data suggest that re-expression of MAGE genes in melanoma might contribute to malignant 
phenotype and interfere with therapy response (Simpson et al., 2005). Other genes found 
hypomethylated in melanoma were MASPIN, a serine protease inhibitor (Wada et al., 2005) 
and TIMP1, a metalloprotease inhibitor (Ricca et al., 2009). While the significance of 
MASPIN expression in melanoma formation and progression requires further investigation, 
TIMP1 expression in melanoma cells seems to be an early event and promotes anoikis 
resistance (Ricca et al., 2009).  
Comparatively to tumor suppressor epigenetic silencing little is known about the role of 
hypomethylation in melanoma development. More studies are necessary to find new target 
genes and repetitive sequences regulated by hypomethylation and their possible role in 
melanocyte malignant transformation. 
3.2 Histone modifications in melanoma 
The study of histone modifications is more complex than DNA methylation, since there are 
many possible combinations of histone marks. Additionally, there is the requirement of 
chromatin immunoprecipitation approaches with specific antibodies for each histone 
modification and the need of large amounts of starting DNA, which is difficult to obtain 
from patients’ tumor samples. Summarizing, these factors restrict the number of studies 
about histone modifications in melanoma. Nevertheless, these problems might be solved by 
the new generation of high-throughput technologies and whole genome amplification 
protocols. Besides the limited data about histone modifications in melanoma, some studies 
have revealed changes in the expression of histone modifying enzymes, as well as aberrant 
changes in the level of global histone modifications in this type of cancer (Richards & 
Medrano, 2008; Molognoni et al., 2011).  
3.2.1 Histone acetylation in melanoma 
Generally, available studies have shown a global reduction of monoacetylated H4K16 in 
many types of cancer (Portela & Esteller, 2010). Loss of acetylation is mediated by histone 
deacetylases (HDACs), which have been found to be over-expressed or mutated in different 
types of tumors (Portela & Esteller 2010). It is important to remember that histone 
deacetylation is linked to inhibition of transcription and histone acetylation with 
transcription activation. In melanoma, until now there are non-specific studies addressing 
the global status of histone acetylation. On the other hand, there are some works showing 
that histone deacetylase inhibitors can re-activate genes that are silenced in melanoma 
(Sigalotti et al., 2010). These genes are involved in important processes, such as apoptosis 
(i.e. BAX, BCL-X), cell cycle (i.e.CDKN1A, CDKN2A), and DNA repair (RAD 50) (Munshi et 
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al., 2006; Valentini et al., 2007; Zhang et al., 2004). Therefore, HDAC inhibitors are currently 
being studied as treatment against the development of malignant melanoma. Apart the 
global loss of histone acetylation and HDACs overexpression, histone acetyltransferases 
(HATs) have been shown altered in cancer cells as well by translocation, mutations, 
deletions and overexpression and have been implicated in the development of various 
tumors (Lafon-Hughes et al., 2008). Moreover, HATs and HDACs are commonly found in 
multi-subunit complexes where their activities and substrate specificities may be altered by 
cofactors and vice versa (Sadoul et al., 2007). The HATs Tip60 and HBO1, for example, are 
present in a complex with the melanoma tumor suppressors ING3 and ING4, respectively. 
Such complexes, important to regulate cell cycle, apoptosis and DNA repair, as well 
important p53 cofactors, are diminished in melanoma (Li et al., 2008, Wang et al., 2007). 
Besides their role in control tumor growth, Tip60 and other HATs (GCN5 and PCAF) can 
stabilize the transcription factor c-Myc, considered as a melanoma oncoprotein (Frank et al., 
2003; Patel et al., 2004, Schlagbauer-Wadl et al., 1999). Furthermore, the HATs CBP and p300 
have been shown associated with microphthalmia-associated transcription factor (MITF), a 
melanocyte lineage survival oncogene that has been related as overexpressed in melanoma 
and associated with decreased survival in patients with metastatic melanoma (Garraway et 
al., 2005; Price et al., 1998; Sato et al., 1997). 
3.2.2 Histone methylation in melanoma 
In addition to acetylation status, studies have demonstrated a possible role of aberrant 
histone methylation in melanoma. Melanoma cells were found to express elevated levels of 
the H3K27 histone methyltransferase EZH2 (McHugh et al., 2007). Moreover, in highly 
metastatic human melanoma cell line A375, there is a decrease in JARID1b histone 
demethylase (known by KDM5B as well) expression. The ectopic expression of JARID1b 
also resulted in cell cycle arrest in G1/S phase, accompanied by decreased cellular 
proliferation and DNA replication (Roesch et al., 2006). These are preliminary data that need 
confirmation in large series of melanoma tissues to define the role of histone methylation in 
melanoma biology. We are far from a clear comprehension of the melanoma histone code 
profile and further investigations will certainly open new avenues in the understanding of 
melanoma formation. 
3.3 MicroRNAs in melanoma 
Like mentioned before, microRNAs (miRNAs) regulate gene expression and are involved in 
the modulation of important cellular processes related with cancer, like apoptosis and cell 
proliferation (Peter, 2010). In this way, alterations in their expression might promote 
tumorigenesis. The study of miRNAs in tumor cells comprises a new scientific field and 
little is known about their roles in melanoma formation and development. The approach 
used at most available works is the hybridization of small RNA fractions isolated from 
cultured cells or tissue samples to specialized miRNA microarrays (Mueller & Bosserhoff, 
2010). Many examples of miRNAs found de-regulated in melanoma cells were identified by 
comparing normal human melanocytes and/or benign nevi with melanoma cell lines or 
tumor tissue samples (Mueller & Bosserhoff, 2010). In this way, two important miRNAs 
found de-regulated in melanoma were described, miR-137 and miR-182, both of them 
regulating MITF, an important gene in melanoma genesis. MiR-137 was found down-
regulated in melanoma cell lines, which resulted in MITF over-expression (Bemis et al., 
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2008). In opposite way, miR-182 was shown to be over-expressed in melanoma, which 
contributed to metastatic potential by repressing MITF and FOXO3 (Segura et al., 2009). 
MiR-182 seems to be involved in melanoma progression since it has been found over-
expressed with the evolution of the disease, from primary to metastatic stages. These 
conflicted alterations might be related to the complex regulation of MITF in melanoma, 
which has been found up-regulated at the beginning phases of tumorigenesis and down-
regulated in cells that acquired invasive and metastatic characteristics (Levy et al., 2006). 
Additionally, Muller and co-workers (2008) showed down-regulation of miRNA let-7 in 
melanomas. Let-7 regulates β3-integrin and according to these authors its down-regulation 
might be responsible for the over-expression of β3-integrin in melanomas.  
The use of specialized miRNA microarrays approach limited the analysis to already known 
miRNAs, restraining the discovery of new miRNAs important in melanocyte 
transformation. To over cross this limitation, Stark and co-workers (2010) employed next-
generation sequencing technology together with microarray profile for studying miRNAs in 
melanoblasts, melanocytes and melanomas. They identified, with this huge study, 279 novel 
miRNAs candidates to be important at the progression of the disease. With this work they 
showed that less-differentiated cell type (melanoblasts) expressed the highest number of 
miRNAs, whereas the most differentiated cell type, the melanocytes, expressed the fewest 
miRNAs species. Melanoma cell lines presented an intermediated number of expressed 
miRNAs. This data is in contrast with what has been shown for other types of cancer. 
Generally, miRNA global expression is up-regulated during differentiation process and 
down-regulated when partial de-differentiation occurs during malignant transformation (Lu 
et al., 2005; Wienholds & Plasterk, 2005). Therefore, the control of miRNA expression during 
melanocytic lineage commitment might be different from the other types of cells. The 
miRNAs studies in cancer are attracting many researchers nowadays, nevertheless more 
studies are necessary to define “melanoma-miRNAs”, as well their importance in disease 
establishment and progression. 
4. Microenvironment and melanoma progression 
In the human skin, melanocytes reside in the epidermis and interact both with keratinocytes 
(cell-cell interaction) and the basement membrane (cell-extracellular matrix interaction). The 
growth and differentiation of melanocytes are tightly regulated by these interactions, which 
are mediated by adhesion molecules, such as cadherins (Tang et al., 1994) and integrins 
(Haass et al., 2005), and by soluble factors (Imokawa, 2004). Cell adhesion complexes, the 
cytoskeleton and the nucleus are linked and changes in the extracellular environment may 
affect the gene expression. In this way, it is now known that changes in this 
microenvironment can result in the disruption of melanocyte homeostasis and melanoma 
development (Haass & Herlyn, 2005; Li et al., 2001; van Kempen et al, 2005), although the 
molecular mechanisms involved are not completely elucidated.  
Epigenetics has provided new insights about the interaction between genome and cellular 
environment. Since alterations in the skin microenvironment (i.e. ultraviolet radiation, 
inflammation, cutaneous wounding) seem to be critical factors for malignant transformation 
(Edwards et al, 1989; Tucker & Goldstein, 2003; van Kempen et al, 2007; von Thaler et al, 
2010) and epigenetic abnormalities may substantially contribute to stress-induced 
pathologies (Johnstone & Baylin, 2010), a better understanding of epigenetic mechanisms 
underlying melanoma genesis may reveal the causal relationship between stress and cancer. 
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In addition, the comprehension of the epigenetics of melanoma could lead to the 
identification of epigenetic marks resulting in aberrant gene expression patterns related to 
initiation and progression of this tumor type and also contribute to the development of new 
therapeutic approaches, the epigenetic drugs, for this malignant tumor. 
5. Experimental models of melanoma genesis 
Experimental models both of murine and human cancers have contributed to a better 
comprehension of tumor biology and provided tools to develop new cancer therapies. In the 
case of melanoma, a variety of in vitro and in vivo models has been utilized, but is important 
to consider the advantages and drawbacks of each model (for review, see Becker et al, 2010; 
Santiago-Walker et al, 2009). Some models may be more suitable for answering a specific 
scientific question than others. Several human melanoma cell lines, mainly from metastatic 
tumors, have provided important information about gene expression profile, genetic 
abnormalities and biological phenotype of melanoma. However, many of these cell lines are 
maintained in culture for long time and, consequently, may accumulate additional 
alterations, not necessarily involved in the acquisition of malignant or metastatic phenotype. 
These cells have been utilized in xeno-transplantation models to analyze the aggressive 
behavior of melanoma, but are not suitable, for example, to study the role of immunological 
components in tumor progression. In the other way, murine syngeneic transplantation 
models have shown as a good option to study melanoma immunology and test new 
immunotherapeutic approaches. Genetically modified animals, in which oncogenes are 
super-expressed or tumor suppressor genes are silenced, have been used to study the role of 
specific genes in the genesis of melanoma (Larue & Beermann, 2007).  
As mentioned before, cellular microenvironment is crucial for maintaining the normal 
function of melanocytes. In this way, some models were established in order to recapitulate, 
as closely as possible, the microenvironment context of the skin (Khavari, 2006). Two-
dimensional melanocyte cultures (with or without keratinocytes), multicellular tumor 
spheroids and, specially, three-dimensional skin reconstructs (although without vascular 
and lymphatic components) have shown excellent ways to mimic skin environment in 
patient’ lesions and can complement the data coming from murine melanoma models.  
Even considering their limitations, mainly regarding the localization of melanocytes in the 
skin (Khavari, 2006), it has been proved that mouse melanoma models may substantially 
contribute to better understand the molecular mechanisms underlying the melanoma 
genesis and also to the evaluation of new drugs and therapies (Becker et al., 2010). 
A linear model of melanocyte malignant transformation associated with sustained stress 
condition was recently established by our group (Oba-Shinjo et al, 2006). In this model, the 
murine lineage of non-tumorigenic melanocytes, melan-a (Bennett et al, 1987), was 
submitted to sequential cycles of anchorage impediment (blockade of cell-extracellular 
matrix interactions), which initially led to evident morphological and gene expression 
alterations and later to the acquisition of a full malignant phenotype (Molognoni et al, 2011). 
Melan-a melanocytes subjected to 1, 2, 3 and 4 deadhesion blockades were named 
respectively 1C, 2C, 3C and 4C cell lines, are non-tumorigenic and correspond to 
intermediate phases of malignant transformation or pre-malignant melanocytes. Different 
melanoma cell lines were established after submitting the spheroids obtained after 4C cell 
line deadhesion to limiting dilution. All clones randomly selected showed to be tumorigenic 
when subcutaneously transplanted into syngeneic mice. Both non-metastatic (for example, 
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4C3-, 4C11-, a1, a2, a3) and metastatic (Tm1, Tm4, Tm5) melanoma cell lines were obtained 
by this process. Some metastatic melanoma lineages (4C3+ and 4C11+) were also established 
from non-metastatic cell lines (4C3- and 4C11-, respectively) after spontaneously loss of p53 
(Figure 1).  
Different expression profile of E- and N-cadherin was observed in the transition phases 
from melan-a to 4C and also from 4C11- to 4C11+ cell lines (unpublished data), suggesting 
first the onset of epithelial to mesenchymal transition (EMT) and later mesenchymal to 
epithelial transition (MET). This data is reinforced by high expression of the key EMT 
regulator, Snail1, in 4C and 4C11- cell lines (unpublished data). Beta-1 integrins, important 
class of adhesion molecules involved in cell-extracellular matrix interactions, present their 
expression increased at the cell surface in metastatic melanoma cell lines. Additionally, 
strong evidences point β1-integrin as target of aberrant N-glycosylation along melanoma 
genesis (unpublished data). In our model, even with the limitations of a mouse model and a 
culture system, sustained stress led to significant alterations both in cell-cell (cadherins) and 
cell-ECM (β1-integrin) adhesion molecules, which have already been well described as 
proteins consistently involved in the loss of human melanocyte homeostasis. 
 
 
Fig. 1. Model of melanocyte malignant transformation associated with sustained stress 
condition 
No treatment with carcinogenic agent or insertion of oncogene was utilized in our model, 
the only stimulus applied on non-tumorigenic melan-a melanocytes leading to malignant 
transformation was a sustained alteration in the microenvironment, the sequential cycles of 
anchorage blockade (Figure 1). As discussed before, the epigenetics seems to be a crucial 
link between environment and disease. In fact, alterations in the global level both of DNA 
methylation and histone marks were detected after few hours of melanocyte anchorage 
impediment. A global DNA hypermethylation was accompanied by increased mRNA and 
protein levels of Dnmt1, 3a and 3b (Campos et al., 2007). Regarding histone marks, elevated 
levels of the activation mark H3K4me3 and silencing mark H3K9me3 was observed in 
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melan-a melanocytes maintained in suspension for 24 hours. Elevated levels of the histone 
deacetylase Sirt1 was also noted during melanocyte deadhesion (unpublished data). 
Recently, Kashiwagi and colleagues (2011) described the association of Sirt1 and Dnmt3b in 
chromatin regions resistant to nuclease, suggesting that Dnmt3b is preferentially recruited 
into hypoacetylated and condensed chromatin. Interestingly, co-immunoprecipitation 
assays revealed Sirt1-Dnmt3b interaction in melan-a melanocytes maintained in suspension, 
but not in adhered melanocytes (unpublished data). It is important to note that deadhered 
melanocytes also presented global DNA hypermethylation. These data suggest that the 
sustained stressful condition of anchorage blockade result in significant changes in the 
chromatin structure, which may have an important impact in the cell fate. 
Comparing some epigenetic marks along melanoma genesis, in our model, an interesting 
pattern came up in which intermediate phases of malignant transformation, represented by 
the pre-malignant 4C melanocytes and non-metastatic 4C11- melanoma cell line, showed 
epigenetic marks characterizing an open chromatin state. Among some of these identified 
marks are increased levels of the activation histone mark H3K4me3, the histone 
methyltransferase MLL1 (responsible for methylating H3K4), the chromatin remodelling 
factor Chd1 (that recognizes the H3K4me3 histone mark), and the stress-related protein and 
histone deacetylase Sirt1 (that deacetylates the H4K16ac histone mark and many other non-
histone proteins) (Molognoni et al., 2011). Regarding DNA methylation, a progressive global 
DNA hypomethylation along melanoma genesis and a drastic reduction in the expression of 
the methyl-binding protein MeCP2 since pre-malignant 4C melanocytes occurs. These results 
suggest that a decrease in MeCP2, protein that recognizes methylated CpGs and is implicated 
in gene repression, takes place before global DNA hypomethylation. Dnmt1 expression is 
increased since pre-malignant 4C melanocytes to metastatic melanoma cells while only 
metastatic melanoma cells present elevated levels of Dnmt3a and no significant difference in 
the expression of Dnmt3b is observed along melanocyte malignant transformation 
(Molognoni et al., 2011). 
An open and highly accessible chromatin is a hallmark of stem cells and essential for their 
ability to give rise to any cell type (plurypotency). Chd1 expression was showed to be 
required to maintain the open chromatin state of pluripotent mouse embryonic stem cells 
and also for somatic cell reprogramming to the pluripotent state (Gaspar-Maia et al., 2009). 
Chd1 seems to promote the disassembly of nucleosomes at promoter regions, resulting in 
active transcription and open chromatin (Persson & Erkwall, 2010). Another molecular 
alteration that corroborates with the hypothesis that a less differentiated phenotype is 
acquired in the beginning of melan-a melanocyte malignant transformation is the increase in 
Sirt1 expression, which is related with pluripotent state. Recently, Calvanese and coworkers 
(2010) demonstrated that Sirt1 down-regulation is necessary for human embryonic stem cell 
differentiation. Low levels of Sirt1 allow the expression of key developmental genes, which 
are epigenetically silenced in first phases of embryogenesis. In this way, Sirt1 has been 
considered a regulator of stem cell pluripotency and differentiation. The elevated expression 
of Snail1, a major transcription factor regulating EMT (Barrallo-Gimeno & Nieto, 2005), also 
reinforces the acquisition of a less differentiated state by pre-malignant 4C melanocytes and 
non-metastatic 4C11- melanoma cells, which present a mesenchymal phenotype, different to 
melan-a melanocytes and metastatic 4C11+ melanoma cells that express low levels of Snail1 
and a epithelial phenotype (unpublished result). Finally, the acquisition of tumorigenic 
properties (transition 4C to 4C11- cell lines) was characterized by the augment of silencing 
histone marks H3K9me3 and H3K27me3, whereas the acquisition of metastatic properties 
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was accompanied by elevated expression of Dnmt3a, the highest grade of global DNA 
hypomethylation, and loss of Sirt1, Mll1, H3K4me3 mark, Chd1 and Snail1 (Molognoni et 
al., 2011). Besides that, a higher number of coding genes and miRNAs has their expression 
up-regulated in the tumorigenic cell lines 4C11- and 4C11+ after treatment with epigenetic 
drugs than in non-tumorigenic melan-a and 4C melanocytes (Molognoni et al., 2011), 
suggesting a higher number of genes and miRNAs aberrantly silenced by abnormal 
epigenetic marks. 
In our model, it is possible that sustained stress condition (cycles of anchorage blockade) 
have led melan-a melanocytes to acquire early epigenetic marks conferring an open 
chromatin state and a less differentiated state in order to adapt the cells to the injury 
conditions and permit, later, the epigenetic reprogramming resulting in an incorrect 
differentiated state characterized by a full malignant phenotype (Figure 2).  
A great number of genes were identified as having their expression abnormally regulated by 
aberrant epigenetic marks in our melanoma genesis model (unpublished data). Among 
them, Tissue Inhibitor of Metalloprotease-1 (Timp1) was described as presenting its 
promoter progressively demethylated along melanoma genesis and its expression increased 
since the early steps of melanocyte malignant transformation (Ricca et al., 2009). Apart its 
well-known function as a metalloprotease inhibitor, this protein regulates many other 
processes, such as cell proliferation and apoptosis (Chirco et al., 2006; Li et al., 1999). Our 
group showed that the expression of Timp1 confers anoikis resistance along melanocyte 
malignant transformation and also favors metastatic process (Ricca et al., 2009). Other 
examples of genes, which aberrant expression along melanoma genesis seems to be 
regulated by epigenetic alterations, are Snail1, Chd1, p14ARF, p16INK4A, Cdkn2b, Cbs, Itga4, Xist, 
Vav1, Serpine1, among others (unpublished data). Although these data came from a murine 
melanoma model, according to Melanoma Molecular Map Project (available online at 
http://www.mmmp.org/MMMP/) consistent parallel was observed in the expression of 
these genes in human melanoma samples. This analysis might provide novel epigenetic 
markers related to prognosis, diagnosis and response to treatment. 
6. Oxidative stress and epigenetic reprogramming 
As mentioned before, stress conditions (i.e., inflammation, UV radiation) have been 
implicated in the genesis of different pathologies, including cancer. Recently, Johnstone and 
Baylin (2010) pointed the emergent link between chronic stress and epigenetic alterations 
and its association with abnormal cell expansion, cellular dysfunction, changes in cell fate in 
cell renewal systems. They proposed that heritable epigenetic changes caused by stress 
could result in the evolution of abnormal cell states that contribute to disease. 
In our model, in which the malignant phenotype was achieved after submitting non-
tumorigenic melanocytes to a sustained stress condition, significant alterations were 
identified in the global DNA methylation level, histone marks and expression of different 
components of the epigenetic machinery (for example, Dnmts, HDACs, HATs, EZh2, 
MeCP2, Chd1, Sirt1). Abnormal epigenetic marks seems to profoundly impact in the 
expression of both coding genes and microRNAs, since different number of coding genes 
and microRNAs was re-expressed along melanoma genesis after treatment with the 
epigenetic drugs (Molognoni et al., 2011). These data strongly suggest a role of aberrant 
epigenetic marks in the initiation and progression of melanoma. 
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Fig. 2. Epigenetic reprogramming along murine melanocyte malignant transformation 
associated with sustained stress 
The anchorage impediment, the driving force for malignant transformation in our model, 
was accompanied by global DNA hypermethylation and increased levels of DNA 
methyltransferases (Dnmts) (Campos et al., 2007) (Figure 2). In addition, elevated production 
of reactive oxygen species (ROS), such as superoxide anion and hydrogen peroxide, and 
nitric oxide characterized oxidative stress in this condition (Campos et al., 2007; Melo et al., 
2011). Reinforcing the association between epigenetic and stress hypothesized by Johnstone 
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and Baylin (2010) and Hitchler and Domann (2007), inhibiting oxidative stress by 
scavenging superoxide anion abrogated epigenetic alterations observed during the 
anchorage blockade (Campos et al., 2007). Moreover, melan-a melanocytes treated with the 
demethylating agent 5-aza-2`-deoxycytidine (Molognoni et al., 2011) or with the eNOS 
inhibitor L-NAME (Melo et al., 2011) before each deadhesion cycles do not transform. ROS-
activated signaling pathways regulating Dnmts protein levels are still unknown and are 
under investigation in our laboratory. These data indicate that abnormal epigenetic patterns 
seems to be one of the initial events in the melanocyte malignant transformation related to 
microenvironment changes characterized by sustained oxidative stress. 
Overall, the mechanisms underlying the regulation of epigenetic marks by oxidative stress 
still need to be elucidated. An instigating study by O’Hagan and coworkers (2008) showed 
the recruitment of the stress-related protein SIRT1 to double-strand DNA breaks induced in 
an exogenous promoter construct of the E-cadherin CpG island, which is frequently 
aberrantly DNA hypermethylated in epithelial cancers. DNA damage caused by oxidative 
stress induces the dissociation of Sirt1 from repetitive sequences and a functionally diverse 
set of genes and its re-localization to DNA breaks to promote repair, resulting in 
transcriptional changes that parallel with those in the aging (Oberdoerffer et al., 2008). 
 
 
Fig. 3. Epigenetic reprogramming as a key contributor to human melanocyte malignant 
transformation associated with chronic stress.  
O’Hagan and coworkers (2008) showed that, at the damage site, SIRT1 recruited epigenetic 
machinery components, such as EZH2 and DNMTs. Most cells had their DNA repaired, but 
a small number of cells presented the exogenous E-cadherin promoter silenced by heritable 
epigenetic marks. A similar event may be occurring in our malignant transformation model, 
since double-strand breaks, revealed by increased levels of γ-H2AX, and elevated levels of 
Sirt1 (unpublished data) were detected during the melanocyte anchorage blockade.  
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It is important to reinforce that ultraviolet radiation, a known environment factor 
predisposing to melanoma development (Autier & Dore, 1998; MacKie, 2006), and even 
inflammation, observed mainly in the early phases of melanoma genesis (Van Kempen et al., 
2005), induces ROS generation. In this way, we can hypothesize that increases in ROS levels, 
caused for example by chronic inflammation, aging and UV radiation, might be responsible 
for aberrant epigenetic marks as a result of fails in the repair of primary DNA damage. It is 
easy to suppose that melanoma development associated with sustained exposition to these 
conditions may be related to oxidative stress and, possibly, to progressive epigenetic 
alterations (Figure 3). 
7. Clinical applications 
Melanoma is one of the most aggressive and radio- and chemo-resistant tumor types. In this 
way, the understanding of epigenetic mechanisms involved with both initiation and 
progression of melanoma could provide new avenues to identify diagnosis and prognosis 
markers and also develop novel therapeutic approaches. 
7.1 Epigenetic tumor markers 
Aberrant DNA methylation marks have some advantages to be used as tumor markers. One 
of these advantages is that DNA methylation is a stable and heritable mark. Additionally, 
DNA is less prone to degradation than RNA and can be easily obtained from patients’ 
samples, such as sputum, serum and urine samples (Herman & Baylin, 2003). Highly 
sensitive techniques for detecting and quantifying DNA methylation are currently available, 
as methylation-specific polymerase chain reaction (Cottrell & Laird, 2003) and bisulfite 
treatment followed by DNA sequencing. 
Aberrant epigenetic marks can be used to assess clinical outcomes or response to therapies. 
Both abnormally hypermethylated and hypomehtylated genes can be used as tumor markers 
in clinical application for early detection of disease, tumor progression, metastatic potential 
and response to therapeutic agents. Different epigenetic biomarkers have been described as 
presenting clinical relevance in different tumor types, such as gliomas, neuroblastomas, 
leukemias, prostate, bladder, lung, and colorectal cancer (Taby & Issa, 2010). However, very 
few data are available concerning both diagnosis/prognosis markers and the predictive 
value of markers in response to therapy in melanoma (Howell et al., 2009; Schinke et al., 
2010). A promising predictive marker of melanoma progression was that reported by Mori 
and coworkers (2006), in which estrogen receptor A (ER-A) methylation was showed as a 
poor prognostic factor for melanoma patients. Recently, Shinojima and colleagues (2010) 
identified zygote arrest 1 (ZAR1) gene, responsible for oocyte-to-embryo transition, as 
frequently aberrant methylated in melanoma surgical specimens and melanoma cell lines, 
but not in normal human epidermal melanocyte cell lines or melanocytic nevi, suggesting 
ZAR1 methylation as an early diagnostic marker for malignant melanoma. The methylation 
of circulating RASSF1A DNA showed to be less frequent in responder melanoma patients 
compared to non-responders to biochemotherapy (Mori et al., 2005). 
7.2 Epigenetic therapy 
Since epigenetic marks are potentially reversible by pharmacologic drugs, a better 
understanding of epigenetic alterations in melanoma may be valuable to establish novel 
therapeutic regimes in the treatment of patients with advanced melanoma. There are two 
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classes of drugs approved by the US Food and Drug Administration (FDA) for cancer 
treatment that affect epigenetic marks: demethylating agents and histone deacetylase 
inhibitors (HDACi). Demethylating agents, as 5-azacytidine (Fenaux et al, 2009) and decitabine 
(Kantarjian et al., 2007), are nucleoside analogues that induce passive DNA demethylation 
through irreversible colavent bond with Dnmts (Issa, 2009). These DNA methylation 
inhibitors have been shown effective in a variety of non-solid tumors, such as acute myeloid 
leukemia and myelodysplastic syndrome, but the earlier clinical trials using decitabine as 
the only drug for solid tumors, including melanoma, have been disappointing (Abele et al., 
1987; Schwartamman et al., 2000). Apart the unsuccessful results obtained by the treatment 
of solid tumors with demethylating agents, a promising use of this drugs relies on combined 
therapies, for examples with immunotherapy and chemotherapy. For melanoma, decitabine 
treatment seems to potentiate the effect of IL-2 therapy (Gollob et al., 2006) and overcome 
the resistance to interferon-induced apoptosis (Reu et al., 2006) in humans. 
HDAC inhibitors target the catalytic domain of HDACs, blocking their substrate recognition 
(Xu et al., 2007). Short-chain fatty acids (such as valproic acid and sodium butyrate), 
hydroxamic acids (such as trichostatin A and vorinostat), benzamides (such as entinostat) 
and cyclic peptides (such as romidepsin) are different classes of HDACs. Among them, 
vorinostat and romidepsin were approved by the US FDA for the treatment of lymphoma 
(Mann et al., 2007). In melanomas and other tumor types, a number of genes involved in 
growth and survival have been described as up-regulated after HDAC inhibitors (Boyle et 
al., 2005; Minucci & Pelicci, 2006). Several HDAC inhibitors are under clinical trials in other 
cancer types, but the results have also indicated low activity in solid tumors (Prince et al., 
2009). Experimental data from combined treatment of the SIRT1/2 inhibitor suramin and the 
xanthine derivative pentoxifylline showed synergistic inhibition of antitumor and 
antimetastatic activity in murine B16F10 melanoma cells (Dua et al., 2007). Valproic acid was 
showed to induce dose-dependent growth arrest, apoptosis, and sensitization to cisplatin 
and ectoposide in M14 human melanoma cells (Valentini et al., 2007). 
An important aspect that needs to be considered about the use of epigenetic drugs in clinical 
practice is that they lack specificity and then may induce the reactivation of normally 
silenced sequences, such as imprinted genes, repetitive sequences and even pro-metastatic 
genes. Although this possibility exists, until now no clinical data support these concerns. 
Drugs selectively targeting specific genes are been investigated and may provide a 
promising future in the cancer therapy. 
8. Conclusions 
Since environmental factors, in special UV radiation, are important risk factors contributing 
to melanoma formation, and epigenetic changes may vary according to environment 
alterations, it is imposed to suppose the role of aberrant epigenetic marks induced by stress 
conditions in the genesis of melanoma. Epigenetics has emerged as a promising field in 
developing novel and efficient drugs against cancer. In this way, efforts should be done in 
order to determine not only genes which aberrant expression as a consequence of abnormal 
epigenetic marks, but also clarify the molecular pathways involved in deregulation of 
epigenetic machinery in response of stress conditions. This knowledge may bring new 
insights concerning chronic stress, epigenetic alterations and melanoma genesis, and also 
may provide novel targets to drug development and epigenetic marks with value in 
diagnosis, prognosis and response to treatment. 
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